Email Alert | RSS

Journal of Peking University (Health Sciences) ›› 2021, Vol. 53 ›› Issue (4): 665-670. doi: 10.19723/j.issn.1671-167X.2021.04.007

Previous Articles     Next Articles

Influence of deep invasive tumor thrombus on the surgical treatment and prognosis of patients with non-metastatic renal cell carcinoma complicated with venous tumor thrombus

ZHAO Xun,YAN Ye,HUANG Xiao-juan,DONG Jing-han,LIU Zhuo,ZHANG Hong-xian,LIU Cheng(),MA Lu-lin()   

  1. Department of Urology, Peking University Third Hospital, Beijing 100191, China
  • Received:2021-03-16 Online:2021-08-18 Published:2021-08-25
  • Contact: Cheng LIU,Lu-lin MA E-mail:chengliu@bjmu.edu.cn;malulinpku@163.com
  • Supported by:
    National Natural Science Foundation of China(82070778)

RICH HTML

   

PDF (PC)

Abstract:

Objective: To evaluate the impact of deep invasive tumor thrombus on the surgical complexity and prognosis of patients with renal cell carcinoma complicated with inferior vena cava tumor thrombus. Methods: We retrospectively reviewed the clinical data of 94 patients with non-metastatic renal cell carcinoma complicated with inferior vena cava tumor thrombus, who underwent surgical treatment in Peking University Third Hospital from January 2017 to June 2020. The patient’s general condition, clinicopathological characteristics, surgery and survival information were collected. The patients were divided into two groups based on the intra-operative findings of tumor thrombus adhesion to the venous wall, of which 64 cases were in the deep invasive tumor thrombus (DITT) group and 30 cases were in the non-invasive tumor thrombus (NITT) group. Chi-square, t test and Mann-Whitney U test were used for categorical and continuous variables respectively. Kaplan-Meier plots and multivariable Cox regressions were performed to evaluate the influence of DITT on the prognosis of the patients with renal cell carcinoma with inferior vena cava tumor thrombus. Results: DITT significantly increase the difficulty of surgery for the patients with renal cell carcinoma with venous tumor thrombus, which was mainly reflected in the longer operation time (362.5 vs. 307.5 min, P=0.010), more surgical bleeding (1 200 vs. 450 mL, P=0.006), more surgical blood transfusion (800 vs. 0 mL, P=0.021), more plasma transfusion (200 vs. 0 mL, P=0.001), a higher proportion of open surgery (70.3% vs. 36.7%, P=0.002), a longer post-operative hospital stay (9.5 vs. 8 days, P=0.036), and a higher proportion of post-operative complications (46.9% vs. 13.8%, P=0.002). DITT was associated with worse overall survival of the patients with renal cell carcinoma with inferior vena cava tumor thrombus (P=0.022). Even in the multivariate analysis, DITT was still a poor prognostic factor for the overall survival of these patients [HR: 4.635 (1.017-21.116), P=0.047]. Conclusion: For patients with non-metastatic renal cell carcinoma with inferior vena cava tumor thrombus, DITT will significantly increase the difficulty of surgery, and may lead to poor prognosis.

Key words: Renal cell carcinoma, Inferior vena cava, Tumor thrombus, Prognosis

CLC Number: 

  • R737.11

Figure 1

Typical CT image appearance of DITT group and NITT group DITT, deep invasive tumor thrombus; NITT, non-invasive tumor thrombus."

Table 1

Comparison of clinical and pathologic features between DITT group and NITT group"

Items DITT (n=64) NITT (n=30) t/U/χ2 P value
Age/years 60.4±8.9 59.4±10.9 0.453 0.652
Gender 3.548 0.060
Male 52 (81.3%) 19 (63.3%)
Female 12 (18.8%) 11 (36.7%)
Side 0.121 0.728
Left 17 (26.6%) 9 (30.0%)
Right 47 (73.4%) 21 (70.0%)
Clinical symptoms 1.294 0.523
No clinical symptoms 13 (20.3%) 7 (23.3%)
Local symptoms 36 (56.3%) 19 (63.3%)
Systemic symptoms 15 (23.4%) 4 (13.3%)
BMI/(kg/m2) 24.7±3.5 24.0±2.8 0.893 0.374
Tumor diameter/cm 8.1±2.9 9.1±2.8 1.684 0.096
Hb/(g/L) 120.3±20.4 130.3±20.7 2.203 0.030
Neu/(×109/L) 4.8±1.7 4.2±1.1 1.784 0.078
Plt/(×109/L) 255.0±118.6 262.7±77.8 0.325 0.746
ALP/(U/L) 91.6±37.6 85.6±22.5 0.802 0.424
Alb/(g/L) 39.1±5.1 40.5±4.4 1.257 0.212
Ca/(mg/L) 2.3±0.2 2.2±0.1 0.552 0.583
SCr/(μmol/L) 100.2±25.3 90.8±20.4 1.766 0.081
SCr after surgery/(μmol/L) 116.5±54.2 101.9±37.7 1.259 0.211
ASA score 5.876 0.053
1 3 (4.7%) 2 (6.7%)
2 50 (78.1%) 28 (93.3%)
3 11 (17.2%) 0 (0)
pN stage 4.099 0.052
N0 56 (87.5%) 30 (100.0%)
N1 8 (12.5%) 0 (0)
Mayo classification 8.755 0.033
Ⅰ 11 (17.2%) 12 (40.0%)
Ⅱ 40 (62.5%) 15 (50.0%)
Ⅲ 8 (12.5%) 0 (0)
Ⅳ 5 (7.8%) 3 (10.0%)
Pathology type 0.424 0.769
Clear cell carcinoma 52 (81.3%) 26 (86.7%)
Non clear cell carcinoma 12 (18.7%) 4 (13.3%)
Fuhrman grade 0.419 0.518
Ⅰ-Ⅱ 27 (42.9%) 15 (50.0%)
Ⅲ-Ⅳ 36 (57.1%) 15 (50.0%)
Surgical approach 9.601 0.002
Laparoscopic surgery 19 (29.7%) 19 (63.3%)
Open surgery 45 (70.3%) 11 (36.7%)
IVC resection 13.464 <0.001
No 42 (65.6%) 30 (100.0%)
Yes 22 (34.4%) 0 (0)
Operative time/min 362.5 (305.3, 429.8) 307.5 (254.5, 374.0) 644.0 0.010
Surgical bleeding volume/mL 1 200 (325, 2 500) 450 (200, 800) 621.0 0.006
Surgical blood transfusion volume/mL 800 (0, 1 600) 0 (0, 600) 689.0 0.021
Plasma transfusion volume/mL 200 (0, 750) 0 (0, 0) 598.0 0.001
Post-operative hospital stay/d 9.5 (7.0, 13.0) 8.0 (6.0, 9.3) 702.5 0.036
Post-operative adjuvant targeted therapy 2.546 0.111
No 23 (35.9%) 16 (53.3%)
Yes 41 (64.1%) 14 (46.7%)
Post-operative complications 9.417 0.002
No 34 (53.1%) 25 (86.2%)
Yes 30 (46.9%) 4 (13.8%)

Table 2

Comparison of surgical features between DITT group and NITT group in Mayo Ⅱ level tumor thrombus subgroup"

Items DITT (n=40) NITT (n=15) U/χ2 P value
Operative time/min 368.5 (306.5, 525.0) 302.0 (258.0, 355.0) 139 0.002
Surgical bleeding volume/mL 1 450 (525, 2 925) 400 (200, 800) 152.5 0.005
Surgical blood transfusion volume/mL 800 (0, 1 600) 0 (0, 400) 202 0.054
Plasma transfusion volume/mL 400 (0, 800) 0 (0, 0) 155 0.003
Post-operative hospital stay/d 11.0 (7.0, 13.0) 8.0 (6.0, 9.0) 190 0.036
Open surgery 30 (75.0%) 4 (26.7%) 10.8 0.001
Post-operative complications 22 (55.0%) 2 (13.3%) 7.7 0.006

Figure 2

Overall survival time between DITT group and NITT group DITT, deep invasive tumor thrombus; NITT, non-invasive tumor thrombus."

Table 3

Multivariate Cox regression analysis of prognosis risk factors for patients with non-metastatic renal cell carcinoma and inferior vena cava tumor thrombus"

Items HR 95%CI P value
DITT 4.635 1.017-21.116 0.047
Mayo classification 2.046 1.161-3.604 0.013
Hb - - 0.484
Non-clear cell carcinoma 4.275 1.495-12.229 0.007
Fuhrman grade (Ⅲ-Ⅳ vs. Ⅰ-Ⅱ) - - 0.719
[1] Ferlay J, Colombet M, Soerjomataram I, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018 [J]. Eur J Cancer, 2018, 103:356-387.
doi: S0959-8049(18)30955-9 pmid: 30100160
[2] Lardas M, Stewart F, Scrimgeour D, et al. Systematic review of surgical management of nonmetastatic renal cell carcinoma with vena caval thrombus [J]. Eur Urol, 2016, 70(2):265-280.
doi: 10.1016/j.eururo.2015.11.034
[3] Quencer KB, Friedman T, Sheth R, et al. Tumor thrombus: incidence, imaging, prognosis and treatment [J]. Cardiovasc Diagn Ther, 2017, 7(Suppl 3):S165-S177.
doi: 10.21037/cdt
[4] González J, Gorin MA, Garcia-Roig M, et al. Inferior vena cava resection and reconstruction: Technical considerations in the surgical management of renal cell carcinoma with tumor thrombus [J]. Urol Oncol, 2014, 32(1): 34.e19-26.
doi: 10.1016/j.urolonc.2013.01.004
[5] Adams LC, Ralla B, Bender YY, et al. Renal cell carcinoma with venous extension: prediction of inferior vena cava wall invasion by MRI [J]. Cancer Imaging, 2018, 18(1):17.
doi: 10.1186/s40644-018-0150-z pmid: 29724245
[6] Psutka SP, Boorjian SA, Thompson RH, et al. Clinical and radiographic predictors of the need for inferior vena cava resection during nephrectomy for patients with renal cell carcinoma and caval tumour thrombus [J]. BJU Int, 2015, 116(3):388-396.
doi: 10.1111/bju.13005 pmid: 25430786
[7] Liu Z, Li L, Hong P, et al. A predictive model for tumor invasion of the inferior vena cava wall using multimodal imaging in patients with renal cell carcinoma and inferior vena cava tumor thrombus [J]. Biomed Res Int, 2020, 2020:9530618.
[8] Li QY, Li N, Huang QB, et al. Contrast-enhanced ultrasound in detecting wall invasion and differentiating bland from tumor thrombus during robot-assisted inferior vena cava thrombectomy for renal cell carcinoma [J]. Cancer Imaging, 2019, 19(1):79.
doi: 10.1186/s40644-019-0265-x
[9] Heng DY, Xie W, Regan MM, et al. External validation and comparison with other models of the international metastatic renal-cell carcinoma database consortium prognostic model: A population-based study [J]. Lancet Oncol, 2013, 14(2):141-148.
doi: 10.1016/S1470-2045(12)70559-4
[10] Xiao R, Xu C, He W, et al. Preoperative anaemia and thrombocytosis predict adverse prognosis in non-metastatic renal cell carcinoma with tumour thrombus [J]. BMC Urol, 2021, 21(1):31.
doi: 10.1186/s12894-021-00796-6
[11] Du S, Huang Q, Yu H, et al. Initial series of robotic segmental inferior vena cava resection in left renal cell carcinoma with caval tumor thrombus [J]. Urology, 2020, 142:125-132.
doi: 10.1016/j.urology.2020.03.053
[12] Gu L, Li H, Wang Z, et al. A systematic review and meta-analysis of clinicopathologic factors linked to oncologic outcomes for renal cell carcinoma with tumor thrombus treated by radical nephrectomy with thrombectomy [J]. Cancer Treat Rev, 2018, 69:112-120.
doi: 10.1016/j.ctrv.2018.06.014
[13] Rodriguez Faba O, Linares E, Tilki D, et al. Impact of microscopic wall invasion of the renal vein or inferior vena cava on cancer-specific survival in patients with renal cell carcinoma and tumor thrombus: A multi-institutional analysis from the International Renal Cell Carcinoma-Venous Thrombus Consortium [J]. Eur Urol Focus, 2018, 4(3):435-441.
doi: S2405-4569(17)30018-4 pmid: 28753848
[14] Wang H, Li X, Huang Q, et al. Prognostic role of bland thrombus in patients treated with resection of renal cell carcinoma with infe-rior vena cava tumor thrombus [J]. Urol Oncol, 2021, 39(5): 302.e1-e7.
doi: 10.1016/j.urolonc.2021.02.005
[1] Junyong OU,Kunming NI,Lulin MA,Guoliang WANG,Ye YAN,Bin YANG,Gengwu LI,Haodong SONG,Min LU,Jianfei YE,Shudong ZHANG. Prognostic factors of patients with muscle invasive bladder cancer with intermediate-to-high risk prostate cancer [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 582-588.
[2] Kewei CHEN,Zhuo LIU,Shaohui DENG,Fan ZHANG,Jianfei YE,Guoliang WANG,Shudong ZHANG. Clinical diagnosis and treatment of renal angiomyolipoma with inferior vena cava tumor thrombus [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 617-623.
[3] Shuai LIU,Lei LIU,Zhuo LIU,Fan ZHANG,Lulin MA,Xiaojun TIAN,Xiaofei HOU,Guoliang WANG,Lei ZHAO,Shudong ZHANG. Clinical treatment and prognosis of adrenocortical carcinoma with venous tumor thrombus [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 624-630.
[4] Jie YANG,Jieli FENG,Shudong ZHANG,Lulin MA,Qing ZHENG. Clinical effects of transesophageal echocardiography in different surgical methods for nephrectomy combined with Mayo Ⅲ-Ⅳ vena tumor thrombectomy [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 631-635.
[5] Binshuai WANG,Min QIU,Qianjin ZHANG,Maofeng TIAN,Lei LIU,Guoliang WANG,Min LU,Xiaojun TIAN,Shudong ZHANG. Experience in diagnosis and treatment of 6 cases of renal Ewing's sarcoma with venous thrombus [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 636-639.
[6] Le YU,Shaohui DENG,Fan ZHANG,Ye YAN,Jianfei YE,Shudong ZHANG. Clinicopathological characteristics and prognosis of multilocular cystic renal neoplasm of low malignant potential [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 661-666.
[7] Fan SHU,Yichang HAO,Zhanyi ZHANG,Shaohui DENG,Hongxian ZHANG,Lei LIU,Guoliang WANG,Xiaojun TIAN,Lei ZHAO,Lulin MA,Shudong ZHANG. Functional and oncologic outcomes of partial nephrectomy for cystic renal cell carcinoma: A single-center retrospective study [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 667-672.
[8] Zezhen ZHOU,Shaohui DENG,Ye YAN,Fan ZHANG,Yichang HAO,Liyuan GE,Hongxian ZHANG,Guoliang WANG,Shudong ZHANG. Predicting the 3-year tumor-specific survival in patients with T3a non-metastatic renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 673-679.
[9] Yangyi FANG,Qiang LI,Zhigao HUANG,Min LU,Kai HONG,Shudong ZHANG. Well-differentiated papillary mesothelial tumour of the tunica vaginalis: A case report [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 741-744.
[10] Yuanyuan ZENG,Yun XIE,Daonan CHEN,Ruilan WANG. Related factors of euthyroid sick syndrome in patients with sepsis [J]. Journal of Peking University (Health Sciences), 2024, 56(3): 526-532.
[11] Jian-bin LI,Meng-na LYU,Qiang CHI,Yi-lin PENG,Peng-cheng LIU,Rui WU. Early prediction of severe COVID-19 in patients with Sjögren’s syndrome [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 1007-1012.
[12] Yun-chong LIU,Zong-long WU,Li-yuan GE,Tan DU,Ya-qian WU,Yi-meng SONG,Cheng LIU,Lu-lin MA. Mechanism of nuclear protein 1 in the resistance to axitinib in clear cell renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2023, 55(5): 781-792.
[13] Huan-rui LIU,Xiang PENG,Sen-lin LI,Xin GOU. Risk modeling based on HER-2 related genes for bladder cancer survival prognosis assessment [J]. Journal of Peking University (Health Sciences), 2023, 55(5): 793-801.
[14] Zi-xuan XUE,Shi-ying TANG,Min QIU,Cheng LIU,Xiao-jun TIAN,Min LU,Jing-han DONG,Lu-lin MA,Shu-dong ZHANG. Clinicopathologic features and prognosis of young renal tumors with tumor thrombus [J]. Journal of Peking University (Health Sciences), 2023, 55(5): 802-811.
[15] Dong LAN,Zhuo LIU,Yu-xuan LI,Guo-liang WANG,Xiao-jun TIAN,Lu-lin MA,Shu-dong ZHANG,Hong-xian ZHANG. Risk factors for massive hemorrhage after radical nephrectomy and removal of venous tumor thrombus [J]. Journal of Peking University (Health Sciences), 2023, 55(5): 825-832.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright © Journal of Peking University (Health Sciences), All Rights Reserved.
Powered by Beijing Magtech Co. Ltd